Fig. 3From: Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trialsForest plots of pooled overall survival in patients with metastatic esophageal cancer. a 1-year PFS. b 2-year PFS. CET, cetuximabBack to article page